Efficacy and safety of JNJ-42165279, a fatty acid amide hydrolase inhibitor, in adolescents and adults with autism spectrum disorder: a randomized, phase 2, placebo-controlled study.
Journal
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907
Informations de publication
Date de publication:
16 Oct 2024
16 Oct 2024
Historique:
received:
03
06
2024
accepted:
24
09
2024
revised:
05
09
2024
medline:
17
10
2024
pubmed:
17
10
2024
entrez:
16
10
2024
Statut:
aheadofprint
Résumé
JNJ-42165279, a highly selective and orally bioavailable fatty acid amide (FAA) hydrolase inhibitor, was evaluated for efficacy and safety in adolescents and adults with autism spectrum disorder (ASD) in this phase 2, double-blind, placebo-controlled, multicenter study (NCT03664232). Participants aged 13-35 years, with a diagnosis of ASD (Diagnostic and Statistical Manual of Mental Disorders, 5th edition; Autism Diagnostic Observation Schedule, 2nd edition) were randomized (1:1) to 12 weeks of treatment with JNJ-42165279 (25 mg, twice-daily) or placebo. Primary endpoints were the change in the Autism Behavior Inventory (ABI) Core Domain (ABI-CD), ABI-Social Communication (ABI-SC), and ABI-Repetitive/Restrictive Behavior (ABI-RB) scores from baseline to day 85. Of the 61 participants (16 female, 45 male) included in the efficacy analyses, 53 (87%) completed the double-blind treatment. At day 85, the JNJ-42165279 group did not show a statistically significant reduction in ASD symptoms versus placebo, as assessed with ABI-CD (p = 0.284), ABI-SC (p = 0.290), and ABI-RB (p = 0.231). However, the following secondary outcomes exhibited small to moderate changes directionally favoring JNJ-42165279: Social Responsiveness Scale 2 (SRS, p = 0.064), Repetitive Behavior Scale-Revised (RBS-R, p = 0.006), Zarit Burden Interview short version (ZBI, p = 0.063), Child Adolescent Symptom Inventory-Anxiety (CASI-Anx, p = 0.048), and Caregiver Global Impression of Severity (p = 0.075). Notably, versus placebo, JNJ-42165279-treated participants showed increased concentrations of FAAs throughout the treatment period, with those achieving elevated concentrations experiencing the greatest reduction in the SRS total score at day 85. JNJ-42165279 demonstrated an acceptable safety profile. Although primary endpoints were not met, JNJ-42165279 may have a therapeutic effect on certain aspects of core ASD symptoms.
Identifiants
pubmed: 39414987
doi: 10.1038/s41386-024-02001-2
pii: 10.1038/s41386-024-02001-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to American College of Neuropsychopharmacology.
Références
American Psychiatric Association D, Association AP. Diagnostic and statistical manual of mental disorders: DSM-5. American Psychiatric Association Washington, DC; 2013.
Baxter AJ, Brugha TS, Erskine HE, Scheurer RW, Vos T, Scott JG. The epidemiology and global burden of autism spectrum disorders. Psychol Med. 2015;45:601–13.
doi: 10.1017/S003329171400172X
pubmed: 25108395
Data & Statistics on Autism Spectrum Disorder. January 25, 2024. Avaialble at: https://www.cdc.gov/autism/data-research/index.html . Accessed 10 April, 2024.
Lamy M, Pedapati EV, Dominick KL, Wink LK, Erickson CA. Recent advances in the pharmacological management of behavioral disturbances associated with autism spectrum disorder in children and adolescents. Paediatr Drugs. 2020;22:473–83.d.
doi: 10.1007/s40272-020-00408-0
Lu H-C, Mackie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016;79:516–25.
doi: 10.1016/j.biopsych.2015.07.028
Devane WA, Hanuš L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946–49.
doi: 10.1126/science.1470919
Solinas M, Goldberg SR, Piomelli D. The endocannabinoid system in brain reward processes. Br J Pharmacol. 2008;154:369–83.
doi: 10.1038/bjp.2008.130
pmcid: 2442437
Fusar-Poli L, Cavone V, Tinacci S, Concas I, Petralia A, Signorelli MS, et al. Cannabinoids for people with ASD: a systematic review of published and ongoing studies. Brain Sci. 2020;10:572.
doi: 10.3390/brainsci10090572
pmcid: 7563787
Pietropaolo S, Bellocchio L, Bouzon-Arnaiz I, Yee BK. The role of the endocannabinoid system in autism spectrum disorders: Evidence from mouse studies. Prog Mol Biol Transl Sci. 2020;173:183–208.
doi: 10.1016/bs.pmbts.2020.04.016
Aran A, Eylon M, Harel M, Polianski L, Nemirovski A, Tepper S, et al. Lower circulating endocannabinoid levels in children with autism spectrum disorder. Mol Autism. 2019;10:2.
doi: 10.1186/s13229-019-0256-6
pmcid: 6354384
Kerr DM, Downey L, Conboy M, Finn DP, Roche M. Alterations in the endocannabinoid system in the rat valproic acid model of autism. Behav Brain Res. 2013;249:124–32.
doi: 10.1016/j.bbr.2013.04.043
pubmed: 23643692
Trezza V, Vanderschuren LJ. Bidirectional cannabinoid modulation of social behavior in adolescent rats. Psychopharmacology (Berl). 2008;197:217–27.
doi: 10.1007/s00213-007-1025-3
pubmed: 18058088
Wei D, Dinh D, Lee D, Li D, Anguren A, Moreno-Sanz G, et al. Enhancement of anandamide-mediated endocannabinoid signaling corrects autism-related social impairment. Cannabis Cannabinoid Res. 2016;1:81–89.
doi: 10.1089/can.2015.0008
pubmed: 28861483
pmcid: 5549436
Keith JM, Jones WM, Tichenor M, Liu J, Seierstad M, Palmer JA, et al. Preclinical characterization of the FAAH inhibitor JNJ-42165279. ACS Med Chem Lett. 2015;6:1204–8.
doi: 10.1021/acsmedchemlett.5b00353
pubmed: 26713105
pmcid: 4677372
Schmidt ME, Liebowitz MR, Stein MB, Grunfeld J, Van Hove I, Simmons WK, et al. The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept study. Neuropsychopharmacology. 2021;46:1004–10.
doi: 10.1038/s41386-020-00888-1
pubmed: 33070154
Hus V, Gotham K, Lord C. Standardizing ADOS domain scores: separating severity of social affect and restricted and repetitive behaviors. J Autism Dev Disord. 2014;44:2400–12.
doi: 10.1007/s10803-012-1719-1
pubmed: 23143131
pmcid: 3612387
Gray SAO Kaufman Brief Intelligence Test. In: Volkmar FR, editor Encyclopedia of Autism Spectrum Disorders. New York, NY: Springer New York; 2013. p. 1673–75.
Pandina G, Ness S, Trudeau J, Stringer S, Knoble N, Lenderking WR, et al. Qualitative evaluation of the Autism Behavior Inventory: use of cognitive interviewing to establish validity of a caregiver report scale for autism spectrum disorder. Health Qual Life Outcomes. 2021;19:26.
doi: 10.1186/s12955-020-01665-w
pubmed: 33472654
pmcid: 7819236
Bangerter A, Ness S, Lewin D, Aman MG, Esbensen AJ, Goodwin MS, et al. Clinical validation of the autism behavior inventory: caregiver-rated assessment of core and associated symptoms of autism spectrum disorder. J Autism Dev Disord. 2020;50:2090–101.
doi: 10.1007/s10803-019-03965-7
pubmed: 30888551
Bangerter A, Ness S, Aman MG, Esbensen AJ, Goodwin MS, Dawson G, et al. Autism behavior inventory: a novel tool for assessing core and associated symptoms of autism spectrum disorder. J Child Adolesc Psychopharmacol. 2017;27:814–22.
doi: 10.1089/cap.2017.0018
pmcid: 5689117
Bangerter A, Manyakov NV, Lewin D, Boice M, Skalkin A, Jagannatha S, et al. Caregiver daily reporting of symptoms in autism spectrum disorder: observational study using web and mobile apps. JMIR Ment Health. 2019;6:e11365.
doi: 10.2196/11365
pmcid: 6454343
Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry. 2007;4:28–37.
pubmed: 20526405
pmcid: 2880930
Guy W. Clinical global impression. Assessment manual for Psychopharmacology. 1976:217–22.
Constantino JN, Gruber CP. Social responsiveness scale: SRS-2. 2012.
Kaat AJ, Lecavalier L, Aman MG. Validity of the aberrant behavior checklist in children with autism spectrum disorder. J Autism Dev Disord. 2014;44:1103–16.
doi: 10.1007/s10803-013-1970-0
Bodfish JW, Symons FJ, Parker DE, Lewis MH. Varieties of repetitive behavior in autism: comparisons to mental retardation. J Autism Dev Disord. 2000;30:237–43.
doi: 10.1023/A:1005596502855
Scahill L, Aman MG, Lecavalier L, Halladay AK, Bishop SL, Bodfish JW, et al. Measuring repetitive behaviors as a treatment endpoint in youth with autism spectrum disorder. Autism. 2015;19:38–52.
doi: 10.1177/1362361313510069
Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist. 1980;20:649–55.
doi: 10.1093/geront/20.6.649
Lecavalier L, Wood JJ, Halladay AK, Jones NE, Aman MG, Cook EH, et al. Measuring anxiety as a treatment endpoint in youth with autism spectrum disorder. J Autism Dev Disord. 2014;44:1128–43.
doi: 10.1007/s10803-013-1974-9
pmcid: 3981870
Virues-Ortega J. Applied behavior analytic intervention for autism in early childhood: meta-analysis, meta-regression and dose-response meta-analysis of multiple outcomes. Clin Psychol Rev. 2010;30:387–99.
doi: 10.1016/j.cpr.2010.01.008
Brugha TS, Doos L, Tempier A, Einfeld S, Howlin P. Outcome measures in intervention trials for adults with autism spectrum disorders; a systematic review of assessments of core autism features and associated emotional and behavioural problems. Int J Methods Psychiatric Res. 2015;24:99–115.
doi: 10.1002/mpr.1466
Meyer, M (2022, May) Development of a Self-Report Tool for Measuring Change in Aspects of Autism. [Poster presentation].International Society for Autism Research, Austin Texas. Avaialble at: https://cdn.ymaws.com/www.autism-insar.org/resource/resmgr/files/insar_2022/2022_Program_Book.pdf . Accessed 20 August, 2024.
Parker KJ, Oztan O, Libove RA, Mohsin N, Karhson DS, Sumiyoshi RD, et al. A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism. Sci Transl Med. 2019;11:eaau7356.
doi: 10.1126/scitranslmed.aau7356
pubmed: 31043522
pmcid: 6716148
Bolognani F, Del Valle Rubido M, Squassante L, Wandel C, Derks M, Murtagh L, et al. A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder. Sci Transl Med. 2019;11:eaat7838.
doi: 10.1126/scitranslmed.aat7838
pubmed: 31043521